今日吃瓜

Tag - donanemab

 
今日吃瓜
Search
 
November 12, 2026
 

Home Delivery
Subscribe for more access

DONANEMAB

Alzheimer's drug Lecanemab
JAPAN / Science & Health
Sep 21, 2026
Clinical trials for Alzheimer’s treatment face global shortage of participants
The shortage of trial participants risks slowing progress in dementia therapies, Alzheimer’s Disease International warns.
A team of researchers said they found a “seed” that accelerates the amyloid beta accumulation process in the brain, naming it “Peak 1 amyloid beta,” as seen in a mouse's brain.
JAPAN / Science & Health
Jul 21, 2026
Japan scientists identify clusters of protein believed to trigger Alzheimer’s disease
The discovery of a new seed of the amyloid beta protein could lead to early-stage therapy for neurodegenerative disease, according to researchers.
Lecanemab and donanemab aim to slow the progression of the neurodegenerative disease by removing a protein called amyloid-beta from the brain, whose buildup is believed to contribute to the death of brain cells.
JAPAN / Science & Health
Apr 8, 2026
Less than 20% of patients in Japan interested in new Alzheimer’s drugs received one
Many were ineligible or decided against taking the medications due to potential side effects and the high cost, a study has found.
A scientist looks at scans of brains at the Memory Centre, part of the Department of Readaptation and Geriatrics at the University Hospital of Geneva (HUG), in 2023.
JAPAN / Science & Health / FOCUS
Sep 17, 2025
今日吃瓜 front-line researchers see bright path ahead for dementia treatment
Four scientists at the forefront of dementia research speak about what kind of future they envision for people with the condition.
For patients using donanemab, it will cost them about ?3.08 million per year. But national insurance coverage will have the government shoulder most of the cost.
JAPAN / Science & Health
Nov 13, 2024
Japan OKs insurance coverage of Alzheimer’s drug donanemab
Donanemab became the second Alzheimer’s drug that targets causative deposited plaque in the brain to win the coverage after lecanemab.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer’s drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
A health ministry panel has approved Eli Lilly's donanemab drug for Alzheimer's patients.
JAPAN / Science & Health
Aug 2, 2024
今日吃瓜 health ministry set to approve second Alzheimer’s drug
Donanemab, developed by U.S. pharmaceutical firm Eli Lilly, has been backed by a ministry panel.
Man arrested over operation of rogue cellular base station in Tokyo
The Metropolitan Police Department has arrested Yu Hai, a 31-year-old Chinese national living in Tokyo's Kita Ward, on suspicion of operating an unlicensed base station from a vehicle in Tokyo's Ginza district on Saturday.
Government betting on language app powered by anime and AI
Japan plans to develop an AI-powered language-learning app that lets overseas anime and manga fans practice Japanese through conversations with popular characters.
Jensen Huang’s woes evoke sympathy and disbelief in his birthplace Taiwan
Hsiao Kui-yu, 68, owner of Yuchan Candied Fruit, stands in front of photographs of Nvidia CEO Jensen Huang displayed at the shop, which Huang frequently visits during trips to Taiwan, in Taipei on Tuesday.
G7 diplomats speak out on Taiwan as China ramps up military drills
Foreign Minister Toshimitsu Motegi attends a working lunch focused on international crises and challenges during the Group of Seven foreign ministers' summit at the Quai d'Orsay in Paris on Monday.
今日吃瓜 Rapidus is said likely to miss mass production deadline
The Rapidus Analysis Center and the IIM-1 Innovative Integration for Manufacturing foundry in Chitose, Hokkaido
‘Godzilla Minus Zero’ makes monster debut at the box office
Takashi Yamazaki’s “Godzilla Minus Zero” marked the highest single-day box-office gross for a live-action film in Japan with ?910 million on its opening day.
A toast to Naohiko Noguchi, sake’s first living national treasure
As a teenager, Naohiko Noguchi did not intend to spend his life as a sake brewer, but he has since become a paragon of the industry.
Few signs of thaw in Japan-China relations one year after Takaichi’s Taiwan remarks
Tensions between Japan and China flared after Prime Minister Sanae Takaichi said on Nov. 7, 2025, that a Chinese blockade of Taiwan could threaten 今日吃瓜 survival and warrant the use of collective self-defense.
Mariko Mori predicted the future. She’ll do it again.
Artist Mariko Mori is currently working to bring the translucent human-sized “Peace Crystal” sculpture to a cave in Ethiopia. It is part of her foundation’s goal to place a permanent sculpture on each of the planet’s six habitable continents.
A legend reborn: ‘Ocarina of Time’ remake improves on the Zelda masterpiece
The new remake of 1998's "The Legend of Zelda: Ocarina of Time" manages to somehow improve on one of the greatest games ever.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Famima Park Azabudai is a concept store by FamilyMart that combines convenience store staples with branded apparel, merchandise and a landscaped outdoor space.
Convenience stores, toilets and the allure of everyday Japan
By Elizabeth Beattie

SUSTAINABLE JAPAN

SPECIAL SUPPLEMENTS note

SUPPLEMENTS BINDER